NOUGUES MAXIMO F 4

What Happened

• Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology (PBYI), received equity awards on February 18, 2026: 46,739 restricted stock units (RSUs) and a derivative award covering 66,541 shares (stock options). Both grants show $0 paid at grant (typical for executive awards as compensation).

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-20 (timely filing).
• Grants reported as: 46,739 shares acquired (RSUs) and 66,541 derivative shares (options); reported price $0.00 at grant.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: The 46,739 RSUs vest in four equal installments (1/4 each) on July 1, 2026; Jan 1, 2027; July 1, 2027; and Jan 1, 2028, subject to continued service.
  • F2: The option award vests and becomes exercisable in the same four equal installments on those dates, subject to continued service.
• No indication in the filing that shares were immediately sold or used to cover taxes (no tax‑withholding or cashless exercise noted).

Context

• RSUs represent a promise to deliver shares upon vesting; options are a right to buy shares once vested (exercise price not provided in the excerpt). Neither grant represents an open‑market purchase or sale — they are compensatory awards. Such grants are common for executive compensation and do not by themselves indicate the insider is buying or selling shares on the market.